Aseptic challenges: the experts' view - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aseptic challenges: the experts' view
Leading pharmaceutical experts talk to Pharmaceutical Technology Europe about trends and challenges in aseptic techniques and technologies.


Pharmaceutical Technology Europe
Volume 21, Issue 12

What are the key challenges to successfully implementing aseptic techniques and technologies?


Nicola Magriotis
Henderson: Some major key challenges with implementing appropriate aseptic techniques and current technologies are centred around clean room design. Retrofitting a conventional clean room with isolator or RABS technology can be difficult because it will often change the air dynamics and may require changes to the existing heating, ventilation and air conditioning (HVAC) systems. Changes in HVAC are extremely expensive, which often deter companies from installing these types of technologies into existing clean rooms. Another key challenge, is implementing technologies and practices that meet multiple regulatory expectations. Companies who market and sell products globally must meet the compliance expectations of many regulatory authorities. Magriotis: Training of operators. Only highly skilled and disciplined operators can ensure the correct implementation of aseptic techniques. Several companies can't (or don't want to) implement aseptic techniques because of inadequate company culture or the inability to establish suitable standard operating procedures (SOPs). These factors sometimes represent real challenges for companies Martin: The primary issue in implementing singleuse systems to replace cleanable stainless steel equipment (filter housings, piping, tanks, filling lines) is the development of extractables data from the singleuse plastic equipment to validate that they do not contribute chemical contaminants to the final product. The Bio-Process Systems Alliance (singleuse trade association) has developed recommendations for single-use equipment suppliers to develop generic extractables data that can be referenced by end users implementing the systems. Suppliers such as Pall have developed libraries of extractables data that can enable users to conduct risk assessments without having to initiate new studies.

What future innovations do you predict in aseptic techniques and technologies during the next 5 years?


Changes to Annex 1 (manufacture of sterile medicinal products)

Pharma fails to comply: top tips from the MHRA
Henderson: In the next 5 years, I believe there will be additional consideration for reducing manual operator interaction during the manufacturing process and making the process more automated. Manual aseptic operations provide a number of uncertainties and risks. Currently, a popular topic for regulatory agencies is risk management of aseptic operations. I believe there will be a large demand to make the process fully automated and thus reduce the associated risk. Magriotis: The use of sterile ready-to-fill vials (as it has already taken place with prefillable syringes). Also, I believe we will see an increased use of plastic, such as cycloolefin copolymer, containers as an alternative to glass. Martin: Rapid microbiology methods will increasingly be employed for bioburden analysis and, in some cases, sterility testing. In addition, automation (robotics) will minimize operator interventions to further reduce the incidence of false positives.

David Henderson Jr Manager, Sterile Filling, Ben Venue Laboratories, Inc.

Nicola Magriotis Macofar Product Line Manager, Romaco Group

Jerold Martin Senior Vice President, Scientific Affairs, Pall Life Sciences


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here